Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias
Jamie J. Manning, Hayley M. Green, Michelle Glass, et al.
Neuropharmacology (2021) Vol. 193, pp. 108611-108611
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 90
THC and CBD: Similarities and differences between siblings
Nephi Stella
Neuron (2023) Vol. 111, Iss. 3, pp. 302-327
Open Access | Times Cited: 58
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials
Margaret Haney, Monique Vallée, Sandy Fabre, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1487-1499
Open Access | Times Cited: 48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery
Lei Tian, Taotao Qiang, Shanglong Liu, et al.
Pharmacology & Therapeutics (2025), pp. 108795-108795
Closed Access | Times Cited: 1
Designer cannabinoids could be the key to pain relief without adverse effects.
Iain R. Greig, Ruth A. Ross
PubMed (2025)
Closed Access | Times Cited: 1
Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects
Tia A. Tummino, Christos Iliopoulos‐Tsoutsouvas, João Braz, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Impact of the mouse estrus cycle on cannabinoid receptor agonist‐induced molecular and behavioral outcomes
Hye Ji J. Kim, Ayat Zagzoog, Tallan Black, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 18
Structure–activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA
Eric Sparkes, Elizabeth A. Cairns, Richard C. Kevin, et al.
RSC Medicinal Chemistry (2021) Vol. 13, Iss. 2, pp. 156-174
Open Access | Times Cited: 19
Endocannabinoid-Binding Receptors as Drug Targets
María Gómez‐Cañas, Carmen Rodríguez‐Cueto, Valentina Satta, et al.
Methods in molecular biology (2022), pp. 67-94
Closed Access | Times Cited: 14
Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence
Jamie J. Manning, Gabriel Rawcliffe, David B. Finlay, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 3, pp. 369-382
Open Access | Times Cited: 10
Large library docking for cannabinoid-1 receptor agonists with reduced side effects
Tia A. Tummino, Christos Iliopoulos‐Tsoutsouvas, João M. Bráz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor
Monica Patel, Natasha L. Grimsey, Samuel D. Banister, et al.
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 5
Essential Dynamics of CB1Receptor-Agonist Complexes: Implications for Signalling Bias
Daniel M. J. Fellner, Michelle Glass, Daniel P. Furkert
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB1 receptor and the consequences on G protein signalling
Jamie J. Manning, David B. Finlay, Michelle Glass
Biochemical Pharmacology (2024) Vol. 224, pp. 116190-116190
Open Access | Times Cited: 1
The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
Dan L. McElroy, Andrew J. Roebuck, Quentin Greba, et al.
IBRO Neuroscience Reports (2022) Vol. 12, pp. 121-130
Open Access | Times Cited: 7
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?
Hayley M. Green, David B. Finlay, Ruth A. Ross, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 12, pp. 1279-1291
Open Access | Times Cited: 7
The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic–Ischemic Brain Injury
Andrea Duranti, Gorane Beldarrain, Antonia Álvarez, et al.
Biomedicines (2022) Vol. 11, Iss. 1, pp. 28-28
Open Access | Times Cited: 7
Linking the G-protein-coupled receptor 55 (GPR55) to the cannabinoid receptors (CB1 and CB2): A new narrative
Paula Morales, Raquel Guerrero‐Alba, Bruno A. Marichal‐Cancino
Elsevier eBooks (2023), pp. 395-406
Closed Access | Times Cited: 3
A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition
Liang Yang, David B. Finlay, Hayley M. Green, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1324-1340
Closed Access | Times Cited: 3
Visualizing an Allosteric Intermediate Using CuAAC Stabilization of an NMR Mixed Labeled Dimer
Paul J. Sapienza, Michelle M. Currie, Noah M. Lancaster, et al.
ACS Chemical Biology (2021) Vol. 16, Iss. 12, pp. 2766-2775
Open Access | Times Cited: 7
Factors Determining Plasticity of Responses to Drugs
Michael J. Parnham, Jennifer Kricker
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2068-2068
Open Access | Times Cited: 4
Biased signalling in analgesic research and development
Alexandra E. Conibear, Christopher Bailey, Eamonn Kelly
Current Opinion in Pharmacology (2024) Vol. 76, pp. 102465-102465
Open Access
A brief review of anandamide in cannabis use and cannabis use disorder
Raesham Mahmood, Claudia Poluga, Isabelle Boileau, et al.
Elsevier eBooks (2024), pp. 285-328
Closed Access
Could positive allosteric modulators of the cannabinoid CB1 receptor be efficacious and safe for the treatment of chronic pain?
Hayley M. Green, Michelle Glass
Current Opinion in Pharmacology (2024) Vol. 79, pp. 102495-102495
Open Access
Chemical Probes for Investigating the Endocannabinoid System
Annaleah Hanske, Marc Nazaré, Uwe Grether
Current topics in behavioral neurosciences (2024)
Closed Access
Page 1 - Next Page

Scroll to top